All Stories

  1. Serum IgA autoantibody profiling in systemic lupus erythematosus reveals associations with disease phenotypes

    Article • RMD Open, July 2026, BMJ

    Dr Fabien B Vincent

  2. Evaluation of primary aldosteronism testing in hypertensive patients with SLE in a tertiary hospital

    Article • Lupus Science & Medicine, February 2025, BMJ

    Dr Fabien B Vincent

  3. Systemic lupus erythematosus in Aboriginal and Torres Strait Islander peoples in Australia: addressing disparities and barriers to optimising patient care

    Article • The Lancet Rheumatology, July 2024, Elsevier

    Dr Fabien B Vincent

  4. Autoimmune rheumatic disease in Australian Aboriginal and Torres Strait Islander Peoples: What do we know?

    Article • Seminars in Arthritis and Rheumatism, April 2024, Elsevier

    Dr Fabien B Vincent

  5. Patterns and prevalence of cognitive dysfunction in systemic lupus erythematosus

    Article • Journal of the International Neuropsychological Society, April 2023, Cambridge University Press

    Dr Fabien B Vincent

  6. Primary aldosteronism: an unsuspected culprit of hypertension in systemic lupus erythematosus?

    Article • Clinical and Experimental Rheumatology, March 2023, Clinical and Experimental Rheumatology

    Dr Fabien B Vincent

  7. Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis

    Article • Lupus Science & Medicine, February 2022, BMJ

    Dr Fabien B Vincent

  8. Circulating Interleukin-37 Levels in Healthy Adult Humans – Establishing a Reference Range

    Article • Frontiers in Immunology, July 2021, Frontiers

    Dr Fabien B Vincent

  9. Long‐term exposure to monoclonal anti‐TNF is associated with an increased risk of lymphoma in BAFF‐transgenic mice

    Article • Clinical & Experimental Immunology, May 2021, Wiley

    Dr Fabien B Vincent

  10. Granulocyte colony‐stimulating factor is not pathogenic in lupus nephritis

    Article • Immunity Inflammation and Disease, May 2021, Wiley

    Dr Fabien B Vincent

  11. GILZ Regulates the Expression of Pro-Inflammatory Cytokines and Protects Against End-Organ Damage in a Model of Lupus

    Article • Frontiers in Immunology, April 2021, Frontiers

    Dr Fabien B Vincent

  12. Advances in Translational Science to Identify New Therapies for Systemic Lupus Erythematosus

    Article • January 2021, Springer Science + Business Media

    Dr Fabien B Vincent

  13. B Cell-Targeted Therapies in Systemic Lupus Erythematosus

    Article • January 2021, Springer Science + Business Media

    Dr Fabien B Vincent

  14. Hallmark of Systemic Lupus Erythematosus: Role of B Cell Hyperactivity

    Article • January 2021, Springer Science + Business Media

    Dr Fabien B Vincent

  15. Associations of metabolic syndrome in SLE

    Article • Lupus Science & Medicine, November 2020, BMJ

    Dr Fabien B Vincent

  16. Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus

    Article • Lupus Science & Medicine, June 2020, BMJ

    Dr Fabien B Vincent

  17. Effect of storage duration on cytokine stability in human serum and plasma

    Article • Cytokine, January 2019, Elsevier

    Dr Fabien B Vincent

  18. Analysis of serum interleukin( IL )‐1α, IL ‐1β and IL ‐18 in patients with systemic sclerosis

    Article • Clinical & Translational Immunology, January 2019, Wiley

    Dr Fabien B Vincent

  19. Analysis of serum B cell‐activating factor from the tumor necrosis factor family ( BAFF ) and its soluble receptors in systemic lupus erythematosus

    Article • Clinical & Translational Immunology, January 2019, Wiley

    Dr Fabien B Vincent

  20. Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus

    Article • Lupus, October 2018, SAGE Publications

    Dr Fabien B Vincent, Professor A. Richard Kitching

  21. Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus

    Article • Lupus Science & Medicine, October 2018, BMJ

    Dr Fabien B Vincent, Professor A. Richard Kitching

  22. Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus

    Article • Frontiers in Immunology, June 2018, Frontiers

    Dr Fabien B Vincent

  23. Analysis of serum macrophage migration inhibitory factor and D‐dopachrome tautomerase in systemic sclerosis

    Article • Clinical & Translational Immunology, January 2018, Wiley

    Dr Fabien B Vincent

  24. Effet des concentrations sériques résiduelles d’anti-TNF et d’anticorps anti-médicaments (ADAb) sur l’efficacité thérapeutique à court terme après switch vers un autre anti-TNF dans la polyarthrite rhumatoïde et la spondyloarthrite axiale

    Article • Revue du Rhumatisme, July 2017, Elsevier

    Dr Fabien B Vincent

  25. Les souris BAFF transgéniques traitées par anti-TNF ont une augmentation du risque de lymphome sous anticorps monoclonaux et pas sous récepteur soluble

    Article • Revue du Rhumatisme, November 2016, Elsevier

    Dr Fabien B Vincent

  26. Effect of serum anti-tumour necrosis factor (TNF) drug trough concentrations and antidrug antibodies (ADAb) to further anti-TNF short-term effectiveness after switching in rheumatoid arthritis and axial spondyloarthritis

    Article • Joint Bone Spine, October 2016, Elsevier

    Dr Fabien B Vincent

  27. Seasonal influenza vaccine coverage of patients on biotherapy for inflammatory joint disease in Normandy, France

    Article • Joint Bone Spine, July 2016, Elsevier

    Dr Fabien B Vincent

  28. Influenza vaccination status in rheumatoid arthritis and spondyloarthritis patients receiving biologic DMARDs

    Article • Joint Bone Spine, March 2016, Elsevier

    Dr Fabien B Vincent

  29. Évaluation du taux de couverture vaccinale contre la grippe saisonnière chez les patients traités par biothérapie pour un rhumatisme inflammatoire en Basse-Normandie

    Article • Revue du Rhumatisme, January 2016, Elsevier

    Dr Fabien B Vincent

  30. Maintien des traitements anti-TNF dans le rhumatisme psoriasique : étude rétrospective monocentrique

    Article • Revue du Rhumatisme, January 2016, Elsevier

    Dr Fabien B Vincent

  31. Tumor necrosis factor inhibitors continuation rates in patients with psoriatic arthritis: A French retrospective monocentre study

    Article • Joint Bone Spine, October 2015, Elsevier

    Dr Fabien B Vincent

  32. BAFF-driven autoimmunity requires CD19 expression

    Article • Journal of Autoimmunity, August 2015, Elsevier

    Dr Fabien B Vincent

  33. The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells

    Article • Leukemia, July 2015, Springer Science + Business Media

    Dr Fabien B Vincent

  34. What has the Young Physician Leaders Programme achieved?

    Article • The Lancet, July 2014, Elsevier

    Dr Fabien B Vincent

  35. Roles of ligands from the TNF superfamily in B cell development, function, and regulation

    Article • Seminars in Immunology, June 2014, Elsevier

    Dr Fabien B Vincent

  36. Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia

    Article • Leukemia, March 2014, Springer Science + Business Media

    Dr Fabien B Vincent

  37. The BAFF/APRIL system in SLE pathogenesis

    Article • Nature Reviews Rheumatology, March 2014, Springer Science + Business Media

    Dr Fabien B Vincent

  38. Glomérulonéphrite à dépôts mésangiaux d’immunoglobulines (Ig)A chez un patient présentant une polyarthrite rhumatoïde traitée par abatacept

    Article • Revue du Rhumatisme, January 2014, Elsevier

    Dr Fabien B Vincent

  39. Mesangial immunoglobulin (Ig)A glomerulonephritis in a patient with rheumatoid arthritis treated with abatacept

    Article • Joint Bone Spine, December 2013, Elsevier

    Dr Fabien B Vincent

  40. The TACI Receptor Regulates T-Cell-Independent Marginal Zone B Cell Responses through Innate Activation-Induced Cell Death

    Article • Immunity, September 2013, Elsevier

    Dr Fabien B Vincent

  41. Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus

    Article • Lupus, July 2013, SAGE Publications

    Dr Fabien B Vincent

  42. The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity

    Article • Cytokine & Growth Factor Reviews, June 2013, Elsevier

    Dr Fabien B Vincent

  43. Focus on systemic lupus erythematosus in Indigenous Australians: towards a better understanding of autoimmune diseases

    Article • Internal Medicine Journal, February 2013, Wiley

    Dr Fabien B Vincent

  44. Clinical associations of serum interleukin-17 in systemic lupus erythematosus

    Article • Arthritis Research & Therapy, January 2013, Springer Science + Business Media

    Dr Fabien B Vincent

  45. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

    Article • Annals of the Rheumatic Diseases, November 2012, BMJ

    Dr Fabien B Vincent

  46. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus

    Article • Immunology and Cell Biology, January 2012, Wiley

    Dr Fabien B Vincent